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Objectives: This study sought to examine the effects and underlying mechanisms of systemic VEGF inhibition
in experimental atherosclerosis and aortic endothelial cells.
Background: Pharmacological inhibition of vascular endothelial growth factor (VEGF), a major mediator of
angiogenesis, has become a widely applied treatment of certain cancers and multiple ocular diseases including
age-related macular degeneration. However, recent clinical trials raise concern for systemic vascular adverse
effects, prompting the Food and Drug Administration to revoke the approval of bevacizumab for metastatic
breast cancer.
Methods: Eight-week old apolipoprotein E knockout mice received a high-cholesterol diet (1.25% cholesterol)
for 24 weeks and were exposed to a systemic pan-VEGF receptor inhibitor (PTK787/ZK222584, 50 mg/kg/d)
or placebo (gavage) for the last 10 weeks. Atherosclerotic lesions were characterized in thoraco-abdominal aor-
tae and aortic arches. Mechanistic analyses were performed in cultured human aortic endothelial cells.
Results: Systemic VEGF inhibition increased atherosclerotic lesions by 33%whereas features of plaque vulnerabil-
ity (i.e. necrotic core size, ﬁbrous cap thickness) remained unchanged compared with controls. Aortic eNOS ex-
pressionwas decreased (trend). In human endothelial cellsVEGF inhibition induced a dose-dependent increase in
mitochondrial superoxide generation with an uncoupling of eNOS, resulting in reduced NO availability and
decreased proliferation.
Conclusion: Systemic VEGF inhibition disrupts endothelial homeostasis and accelerates atherogenesis, suggesting
that these events contribute to the clinical cardiovascular adverse events of VEGF-inhibiting therapies. Cardio-
vascular safety proﬁles of currently applied anti-angiogenic regimens should be determined to improve patient
selection for therapy and allow close monitoring of patients at increased cardiovascular risk.© 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Considerable advances in the understanding of the signiﬁcance of
angiogenesis in tumor growth and neovascular ocular diseases have
boosted the development and clinical application of anti-angiogenic
therapies in the last decade [1–3].Foundation, Bern, Switzerland
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er CC BY-NC-ND license.Pharmacological inhibition of vascular endothelial growth factor
(VEGF) improved clinical outcomes in different cancer entities [4–6]
and revolutionized the treatment of neovascular age-relatedmacular de-
generation (AMD), a leading cause of blindness in the developed world
[7–10]. In addition, intravitreal anti-VEGF therapy has become the stan-
dard of care formacular edema secondary to retinal vein occlusion (RVO)
or diabetic retinopathy (diabetic macular edema, DME) [11,12].
However, evidence from recent meta-analyses of randomized con-
trolled trials using anti-angiogenic regimens in cancer (i.e. non-small
cell lung cancer, metastatic colorectal cancer, and renal cell carcinoma)
accumulates that unanticipated, potentially life-threatening cardiovas-
cular side effects occur upon VEGF inhibition: They include hyperten-
sive emergencies and arterial thrombembolic events encompassing
myocardial infarction, cerebrovascular insults, and peripheral or mes-
enteric ischemia [13–16]. Indeed, in light of signiﬁcant cardiovascular
2454 S. Winnik et al. / International Journal of Cardiology 168 (2013) 2453–2461side effects, the Food and Drug Administration (FDA) revoked its ap-
proval of bevacizumab (Avastin®) for the ﬁrst-line treatment of pa-
tients with HER2-negative metastatic breast cancer in November 2011
[17]. Despite completed phase III clinical trials the cardiovascular safety
proﬁle of VEGF-scavenging based therapies of AMD, RVO and DME pa-
tients using either ranibizumab (Lucentis®), bevacizumab (Avastin®)
or the recently approved aﬂibercept (Eylea®) remains insufﬁciently
assessed and thus raises considerable concern [18,19]. All agents enter
systemic circulation after intraocular injection, indicating a prolonged
systemic suppression of VEGF for up to 28 days or longer [2,9,20,21].
The markedly overlapping risk factor proﬁle for the development of
AMD and atherosclerotic disease suggests that both diseases tend to
occur in the same patient population. Similarly, in RVO and DME pa-
tients cardiovascular co-morbidities are most common. Therefore, the
cardiovascular safety proﬁle of the exponentially increasing anti-
angiogenic therapy regimens formultiple ocular and oncologic diseases
needs to be carefully addressed.
Vascular toxicity has been reported irrespective of the mode of VEGF
blockade, i.e. both upon treatment with VEGF-trapping antibodies and
upon application of receptor tyrosine kinase inhibitors, indicating com-
mon underlying mechanisms [22]. Of note, evidence for a beneﬁcial
role of VEGF inhibition in vascular biology remains highly controversial
[23]. Both systemic and local VEGF gene transfer protected from
neointimal growth, a phenomenon that has been reported to be in part
NO-dependent [24–26]. Concomitantly, systemic VEGF gene transfer
did not enhance experimental atherosclerosis [27]. A single intraperito-
neal application of VEGF, however, did increase atherosclerosis in
different animal models [28]. Based on human autopsy samples and ex-
perimental analyses, neoangiogenesis-dependent intra-plaque hemor-
rhage and subsequent macrophage inﬁltration through vasa vasorum
has been postulated to promote progression and instability of coronary
atheromata [29,30]. However, no evidence for increased atherosclerosis
upon systemic or intramyocardial VEGF applicationwas reported in clin-
ical trials [31–33]. A VEGF polymorphism going along with higher VEGF
expression was even associated with athero-protective effects [34].
In light of the increasing number of patients receiving anti-
angiogenic therapies, this study sought to elucidate the effects of
VEGF inhibition on the progression of atherosclerotic lesions in a
proof-of-principle study. We therefore used an approach in which
mice with existing atherosclerotic lesions were treated systemically
with a pan-VEGF receptor inhibitor,mimicking the situation of elderly
patients receiving anti-angiogenic therapy.
2. Methods
2.1. Animals and diets
Micewere housed in cages with access to food andwater in a temperature-controlled
room with a 12-hour dark/light cycle. All experiments and animal care procedures were
approved by the local veterinary authorities and carried in accordance with our institu-
tional guidelines. 8-week-old male C57BL/6 apolipoprotein E knockout (ApoE-/-) mice
(Jackson Laboratories) were fed a 1.25 % (wt/wt) cholesterol diet (Research Diets) for
24 weeks, and were exposed to a systemic pan-VEGF-receptor inhibitor (PTK787/
ZK222584, 50 mg/kg/d, Novartis, [35] in the following termed “PTK787”) or placebo by
gavage for the last 10 weeks of treatment.
2.2. Assessment of atherosclerosis
For en face analyses thoraco-abdominal aortaewere excised andopened longitudinally.
Atherosclerotic plaques were visualized by fat staining, and analyzed en face as described
[36,37]. Complementary analyses of plaque size and composition were performed in serial
longitudinal cryosections of aortic arches as described [38]. Fibrous cap thickness and ne-
crotic core size were assessed by Elastic van Gieson’s (EvG) staining [39].
2.3. Immunohistochemistry and immunoﬂuorescence
Cryosections were blocked and stained using the following antibodies: rat anti-
CD68 (Serotec), rat anti-CD31 (BD Pharmingen), rabbit anti-von Willebrand Factor
(vWF, Dako), rabbit anti-endothelial nitric oxide synthase (eNOS, Santa Cruz Biotech-
nology), and mouse anti-proliferating cell nuclear antigen (PCNA, Dako). Collagen
was visualized using EvG staining.2.4. Blood analyses
Mice were fasted over night before blood was drawn prior to harvesting. Whole
blood was assessed for complete blood counts. For plasma analyses citrate plasma
was separated from corpuscular elements by centrifugation at 4 °C immediately after
blood was drawn and stored at −80 °C until analysis. Plasma values of interferon
gamma (IFNγ), interleukin 10 (IL-10), IL-1ß, IL-6, and tumor necrosis factor alpha
(TNFα) were determined using multiplex array systems (BD Medical Supplies).
2.5. Functional in vitro analyses
Human aortic endothelial cells (HAEC, Cambrex) from passage ﬁve to eight were
grown to conﬂuence at 5% CO2 and 37 °C. Functional in vitro assays were carried out
24 h after administration of the indicated concentrations of drug or vehicle (DMSO, 0.1%
vol/vol). Proliferation was assessed by bromodeoxyuridine (BrdU, Roche Diagnostics) in-
corporation over 18 h, beginning 6 h after anti-angiogenic treatment. Real-time nitric
oxide (NO) generation was investigated through ﬂuorogenic diaminoﬂuorescein-
diacetate (DAF2-DA, Sigma-Aldrich) transformation. Intracellular superoxide generation
was analyzed using election spin resonance (ESR) spectroscopy as described using
the spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetra-methylpyrrolidine (CMH,
Noxygen) [40].Mitochondrial superoxide generationwas investigated through the oxida-
tion and ﬂuorogenic nucleic acid binding of a mitochondrial- and superoxide-speciﬁc
probe (MitoSOX™, Invitrogen). Cytotoxicity was assessed by lactate dehydrogenase
(LDH) release into the supernatant using a commercially available Cytotoxicity Detection
kit (Roche Diagnostics). NADPH oxidase activity was quantiﬁed through colorigenic con-
version of extracted NADPH using an NADPH/NADP Assay kit (Abcam).
2.6. Expression analyses
For in-cell protein analyses, HAECswereﬁxed in96-well plates, permeabilized and in-
cubated with rabbit anti-eNOS (Santa Cruz). Speciﬁc signals were detected using
near-infrared ﬂuorophore-labeled species-speciﬁc secondary antisera (Licor Biosciences)
and quantiﬁed in a LI-COR Odyssey® Scanner. Signals were normalized to DNA content
detected by the far-red ﬂuorescent DNA dye DRAQ5™ (Biostatus).
To assess uncoupling of the functional eNOS homodimer, HAEC lysates were sepa-
rated by electrophoresis under non-denaturing conditions at 4 °C, blotted, and incu-
bated with rabbit anti-eNOS (Santa Cruz). The speciﬁc signal was detected using
species-speciﬁc secondary antisera.
2.7. Statistical analyses
Metric variables were assessed for distribution using Kolmogorov–Smirnov tests;
variances of different groups were compared by F tests. Different groups were com-
pared using unpaired Student’s t tests, Mann–Whitney U tests, one-way ANOVA or
Kruskal–Wallis tests where appropriate, followed by Dunn’s Multiple Comparison
tests where applicable. Results are displayed as interquartile ranges ± minimal/maximal
values or mean ± SEM, if not indicated differently. At least three independent
experiments in triplicates were performed. Signiﬁcance was accepted at p b 0.05,
p values are two-sided. Analyses were done using Graphpad Prism version 5.0d 2010.
The authors of this manuscript have certiﬁed that they comply with the Principles
of Ethical Publishing in the International Journal of Cardiology.
3. Results
3.1. Systemic VEGF-R inhibition increases experimental atherosclerosis
PTK787 treatment of ApoE-/- mice resulted in a signiﬁcant increase
in atherosclerosis as assessed both in thoraco-abdominal aortae en
face and in longitudinal cross sections of the aortic arch (Fig. 1A, B).
Moreover, we observed a trend towards an enhancement of plaque-
resident CD68-positive macrophages after VEGF-R inhibition, indicat-
ing increased vascular inﬂammation (Fig. 1C). Plasma levels of circu-
lating inﬂammatory cytokines, including IFNγ, IL-10, IL-1ß, IL-6,
and TNFα did not differ between the intervention and the control
group (Table 1A), suggesting a local vascular effect. Concomitantly,
no differences in the white blood cell counts and differentials were
observed (Table 1B).
3.2. VEGF-R inhibition does not affect features of plaque stability or the
number of plaque-resident endothelial cells
To assess putative effects on plaque architecture we compared ne-
crotic core diameters and areas aswell asﬁbrous cap thicknesses. In col-
lagen stainings no differenceswere observed (Fig. 2). Signs of decreased
intra-plaque neoangiogenesis after VEGF-R inhibitionwere investigated
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Fig. 1. Systemic VEGF-R inhibition increases atherosclerotic plaque burden: 8-week-old male ApoE-/- mice on a high cholesterol diet (1.25% w/w) were exposed to the pan-VEGF receptor
[VEGF-R] inhibitor PTK787 (50 mg/kg/d, gavage) or placebo for 10 weeks before aortae were explanted and atherosclerotic lesions assessed. (A) Thoraco-abdominal aortae en face, oil
red o staining (purple), scale bars = 1 mm. n = 10 per group. (B, C) Photomicrographs of aortic arches, longitudinal sections, oil red o- [ORO-] (B) and CD68- (C) staining (both purple),
scale bars = 1 mm, n = 5 per group. *p b 0.05, **p b 0.01; graphs show interquartile ranges, whiskers indicate minima and maxima.
2455S. Winnik et al. / International Journal of Cardiology 168 (2013) 2453–2461by tracking endothelial-speciﬁc markers in atherosclerotic lesions. Sig-
nals for CD31 and vWF in the atherosclerotic aortic wall did not differ
between the intervention and the control group (Fig. 3).3.3. Inhibition of VEGF-R decreases proliferating cells within
atherosclerotic lesions
Local functional effects in the aortic wall were characterized by
assessing cellular proliferation and the expression of eNOS. The number
of proliferating cells as assessed by PCNA stainings in the aortic wall
was decreased upon VEGF-R inhibition (Fig. 4A). eNOS-speciﬁc signals
tended to be reduced in the endothelial layer of intervention group com-
pared with controls, however without reaching signiﬁcance (Fig. 4B).3.4. In human aortic endothelial cells VEGF-R inhibition diminishes eNOS
expression and function in a dose-dependent fashion
To gain further insight into the mechanisms of VEGF-R inhibition in
the vascular wall, dose-response experiments were performed in
human aortic endothelial cells. Following up on the trend towards re-
duced eNOS expression in vivo, we observed a dose-dependent decrease
of eNOS in human aortic endothelial cells in response to PTK787
(Fig. 5A). Moreover, enzymatic function of eNOS was diminished upon
PTK787 treatment in a dose-dependent manner as assessed by
uncoupling experiments (Fig. 5B). Accordingly, endothelial nitric oxide
release was impaired when inhibiting VEGF receptors in human aortic
endothelial cells (Fig. 5C). Given the delicate balance of endothelial nitric
oxide and reactive oxygen species, we assessed the effect of VEGF-R
Table 1
VEGF-R inhibition does not affect levels of plasma inﬂammatory cytokines or blood leu-
kocyte counts.
Placebo PTK787 p value
A. Plasma cytokine proﬁle (pg/ml)
IFNγ 1.38 ± 0.27 1.17 ± 0.45 0.886
IL-10 49.93 ± 7.44 56.13 ± 21.87 1.000
IL-1ß 34.28 ± 3.41 28.22 ± 3.03 0.400
IL-6 25.23 ± 2.59 38.70 ± 8.91 0.200
TNFα 3.00 ± 1.15 2.34 ± 0.30 1.000
B. White blood cell count and differential (103/μl)
Leukocytes 4.22 ± 0.26 5.25 ± 0.72 0.314
Lymphocytes 1.46 ± 0.22 1.50 ± 0.08 0.329
Monocytes 2.11 ± 0.30 3.18 ± 0.67 0.152
Neutrophils 0.13 ± 0.019 0.20 ± 0.13 0.407
ApoE-/- mice on a high cholesterol diet (1.25% wt/wt) were exposed to the pan-VEGF re-
ceptor inhibitor PTK787 for 10 weeks (50 mg/kg/d, gavage) and their whole blood
or plasma was obtained for cell count or cytokine analyses. Pro- and anti-inﬂammatory
cytokine levels (A) and the number of leukocytes as well as their main subpopulations
(B)were unaltered. n = 5 per group, means ± SEM.
2456 S. Winnik et al. / International Journal of Cardiology 168 (2013) 2453–2461inhibition on intracellular superoxide generation; PTK787 treatment re-
vealed a dose-dependent increase (Fig. 5D, Fig. 5G-H).3.5. Inhibition of VEGF-R increases mitochondrial superoxide generation
and decreases endothelial proliferation
Considering the magnitude of the effect of VEGF-R inhibition
on intracellular superoxide generation in human aortic endothelialplacebo
Ev
G
A
m
a
gn
ifie
d
necrotic core
0
10
60
80
100
di
am
et
er
 [%
 to
tal
] 
placebo PTK787
p=0.905
B
0
10
20
30
40
placebo
a
re
a
 [%
 to
tal
] 
necro
p=
Fig. 2. Systemic VEGF-R inhibition does not alter features of plaque vulnerability in experimen
ApoE-/- mice treated with PTK787 or placebo; Elastic van Gieson’s [EvG] stain, top: scale
130 μm, dotted straight lines indicate necrotic core diameters, dotted curved lines indicate
of necrotic core diameter, acellular necrotic core area, and ﬁbrous cap thickness, n = 5 percells, other sources of intracellular superoxide production were
assessed. No difference in NADPH oxidase activity occurred upon
PTK787 treatment (Fig. 6D). However, we observed a signiﬁcant dose-
dependent increase in mitochondrial superoxide levels (Fig. 6A, B). In
fact, endothelial mitochondria were a major source of total intracellular
superoxide generation after VEGF-R inhibition in human aortic endo-
thelial cells (Fig. 6C).
4. Discussion
4.1. Principal ﬁndings
Our data suggest the following sequence of events that link systemic
VEGF-R inhibition to accelerated progression of atherosclerosis: VEGF
inhibition increasesmitochondrial superoxide generation in arterial en-
dothelial cells. Resultant uncoupling of the functional eNOS homodimer
leads to a deterioration of its enzymatic function and an imbalance in
endothelial superoxide and nitric oxide production. The subsequent de-
cline in the functional integrity of the endothelialmonolayer accelerates
the progression of pre-existing atherosclerosis. This disruption of arteri-
al endothelial homeostasis may be one of the mechanisms underlying
the cardiovascular adverse events described in recent meta-analyses
of current anti-angiogenic therapies [13–16,41].
4.2. Added value of the current study
This proof-of-principle study sheds further light on the potential
vascular sequelae of systemic VEGF inhibition and improves our
understanding of the putative mechanisms mediating acceleratedPTK787
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Fig. 3. Systemic VEGF-R inhibition does not affect the number of plaque-resident endothelial cells: Micrographs of longitudinal sections of aortic arches from ApoE-/- mice treated with
PTK787 or placebo are displayed. (A) CD31 staining (purple). Arrows indicate nucleated CD31-positive signals (B) Von Willebrand Factor [vWF] staining (green), nuclei (blue). Ar-
rows indicate nucleated vWF-positive signals. vWF-positive area was normalized to the number of nuclei. Scale bars = 100 μm, n = 5 per group, graphs show interquartile ranges,
whiskers indicate minima and maxima.
2457S. Winnik et al. / International Journal of Cardiology 168 (2013) 2453–2461progression of atherosclerosis in this context. Most patients undergo-
ing anti-angiogenic treatment are aged 50 years or older as in the
case of AMD, DME or RVO treatment, where average patient age is
about 80 years [4,5,9,10]. Especially AMD patients are particularly
prone to pre-existing atherosclerotic changes. Exposure of mice to a
high-cholesterol diet before systemic VEGF-R inhibition in the current
study reﬂects this situation of elderly patients with pre-existing ath-
erosclerosis at the time of the initiation of VEGF-inhibiting therapy.
We have used a receptor tyrosine kinase inhibitor with a high afﬁn-
ity for VEGF-R2 [42] which is known to mediate pro-angiogenic signal-
ing of VEGF-A [1]. Thus, our data represent the effects of a putative
common mechanism underlying the different currently applied anti-
angiogenic regimens. Qualitative analyses of atherosclerotic plaques
allow the appraisal of both atherosclerotic progression (including hall-
marks such as intimal macrophage inﬁltration and intra-plaque neo-
angiogenesis) and features of plaque vulnerability (i.e. ﬁbrous cap
thickness, necrotic core size). Previous ﬁndings correlate genetic or
pharmacological delivery of VEGF with increased levels of NO [26,43].
Our data in which VEGF-R inhibition reduced endothelial NO release
corroborate this concept. We provide additional mechanistic insight
reporting an increase inmitochondrial superoxide generation and asso-
ciated eNOS uncoupling in response to VEGF-R inhibition. The use
of human aortic endothelial cells helps translating our ﬁndings to thehuman arterial endothelial lining. The dose-dependency of our results
mirrors dose-dependent occurrence of clinical cardiovascular toxicities
of current VEGF-R antagonists [13,44].
4.3. Important differences to other studies
Wedid not administer recombinant VEGF or genetically overexpress
VEGF to presumably supra-physiological concentrations as has been
done in previous studies [24–27,43]. In the current study, VEGF-
signaling was inhibited without altering physiological VEGF concen-
trations, as is the case in patients receiving current anti-angiogenic
regimens. Previous experimental studies have shown a VEGF-R2-
mediated increase in NO levels after VEGF gene transfer using venous
endothelial cells [26,43]. The current study substantiates these ﬁndings
in a different setting, assessing the effects of VEGF inhibition in
atherosclerosis-prone arterial vessels in vivo and extends mechanistic
insight in human aortic endothelial cells. Our ﬁndings may therefore
translate into the mechanisms associated with accelerated atheroscle-
rosis and subsequent atherothrombotic events, the most threatening
adverse events of current anti-angiogenic regimens [13–16,18,19].
Well-known clinical studies investigating human coronary autop-
sy samples have postulated that neoangiogenesis within atheroscle-
rotic lesions, associated intra-plaque hemorrhage and macrophage
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Fig. 4. Systemic VEGF-R inhibition attenuates proliferation and endothelial eNOS expression (trend) in aortic atherosclerotic lesions: Immunoﬂuorescent stainings of aortic arches
(longitudinal sections) from ApoE-/-mice treatedwith PTK787 or placebo are displayed. (A) Proliferating Cell Nuclear Antigen [PCNA] staining (green), scale bars = 50 μm(B) endothelial
nitric oxide synthase [eNOS] staining (green), nuclei (blue), scale bars = 1 mm (top) and 350 μm (bottom). *p b 0.05, graphs show interquartile ranges, whiskers indicate minima and
maxima; n = 5 per group.
2458 S. Winnik et al. / International Journal of Cardiology 168 (2013) 2453–2461inﬁltration, may accelerate the progression of atherosclerosis and the
formation of unstable atheromata [29]. Accordingly inhibition of
VEGF-dependent neovascularization has been reported to decrease
experimental atherosclerosis [30]. Interestingly, the data of the
current study cannot conﬁrm these ﬁndings: VEGF-R inhibition accel-
erated athero-progression without affecting features of plaque vul-
nerability. Differences in drug effects or the experimental set-up
(e.g. affecting the maturity of atherosclerotic lesions exceeding oxygen
diffusion distances) may account for these opposing experimental ﬁnd-
ings. Whereas others report on increased atherosclerosis upon intraper-
itoneal VEGF application in different animalmodels [28], in several other
studies no effect on atherosclerosis upon local or systemic VEGF gene
transfer was observed [24,25,27]. Importantly, also no evidence of in-
creased atherogenesis in clinical trials using recombinant VEGF or gene
transfer exists [31–33]. On the contrary, a genetic polymorphism leading
to increased VEGF expression was associated with atheroprotectiveeffects [34], a ﬁnding in line with the data of the present study, and
with accumulating evidence for cardiovascular adverse effects of current
VEGF-inhibiting therapies. The vascular effects of VEGF appear to
markedly depend on local VEGF concentrations, with low amounts nec-
essary for vascular homeostasis and high concentrations resulting in
vasculoproliferative effects [23,45]. In the context of atherosclerosis
this dose-dependency may account for the opposing effects described
in different settings. Importantly, outcome data of current clinical anti-
angiogenic therapies indicate that inhibition of physiological concentra-
tions of VEGF is associatedwith accelerated progression of atherosclero-
sis [13–16,18,19].
4.4. Potential limitations
This study has to be interpreted in light of the following limitations:
In the mouse model of atherosclerosis used in this study, assessment of
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2459S. Winnik et al. / International Journal of Cardiology 168 (2013) 2453–2461hypoxia-driven neoangiogenesis in the plaque center is limited since
the maximal oxygen diffusion distance of about 150 μm may have
not been reached. To minimize this model-based shortcoming, we ex-
posed the mice to a prolonged high-cholesterol diet aiming for lesion
diameters ≥ 150 μm.We chose this model since a range of atheroscle-
rotic lesions very similar to the ones in human atherogenesis develops:
from initial stages of simplemacrophage foam cell morphology tomore
complex lesions consisting of acellular lipid cores and ﬁbrous caps are
seen [46]. Yet we acknowledge that advanced human atherosclerotic
plaques differ frommurine ones inmany aspects – particularly with re-
gard to their thickness.
The use of an agent different from the ones used in current clinical
applications may limit extrapolations to the clinical side effects of onespeciﬁc anti-angiogenic regimen. Based on current meta-analyses de-
scribing very similar cardiovascular adverse effects in different VEGF-
inhibiting regimes, we propose a common underlying mechanism.
Therefore, we chose a receptor tyrosine kinase inhibitor with a high af-
ﬁnity for VEGF-R2 that appears to be a common denominator of all cur-
rent anti-angiogenic therapies.
4.5. Implications
In conclusion, the current study strengthens the rising concern for
potentially life-threatening systemic cardiovascular side effects of cur-
rent anti-angiogenic therapies both in oncology and ophthalmology. A
disruption of endothelial homeostasis with subsequently accelerated
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Fig. 6. VEGF-R inhibition increases mitochondrial superoxide generation in human aortic endothelial cells: Human aortic endothelial cells [HAEC] were incubated with the indicated
doses of PTK787 or vehicle for 24 h and subjected to biochemical analyses. (A) Mitochondrial superoxide (red) generation, representative micrographs of HAEC after incubation
with a ﬂuorogenic mitochondrial-speciﬁc superoxide indicator (MitoSOX™, 5 μM, 10 min), nuclei (blue), left panel: representative magniﬁcation of a single cell. (B) Quantiﬁcation
of mitochondrial superoxide generation. (C) Relative comparison of total intracellular superoxide (dotted line) and mitochondrial superoxide generation (solid line). (D) NADPH
oxidase activity, relative turnover of extracted NADPH. Scale bars = 50 μm, ***p b 0.001.
2460 S. Winnik et al. / International Journal of Cardiology 168 (2013) 2453–2461atherogenesis may be one of the mechanisms underlying these cardio-
vascular adverse effects.
Given the increased cardiovascular risk of elderly patients –
representing the typical target population receiving anti-angiogenic
therapies – and the increasing number of patients treated, the cardio-
vascular safety proﬁle of all current anti-angiogenic regimens should
be precisely determined. The identiﬁcation of biomarkers for cardio-
vascular side effects, as exempliﬁed by Scappaticci and colleagues in
their meta-analyses including a total of 1745 patients with metastatic
colorectal-, breast or non-small cell lung cancer [16], may ease patient
selection for therapy and close monitoring of those at increased
cardiovascular risk. Further subgroup analyses of existing randomized
controlled trials and reporting of careful cardiac assessment of pa-
tients at baseline in future trials will guide the respective cardiovas-
cular prevention in future. The development of alternative drug
delivery strategies such as local gene delivery, speciﬁcally in the con-
text of neovascular ocular diseases may reduce systemic adverse
effects [47]. The cardiovascular adverse effects of currently appliedVEGF-inhibiting approaches highlight the need for clinicians of differ-
ent subspecialties to team up for an improved clinical outcome in an
increasingly complex medical environment.
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